SCHEMBL2200591

SCHEMBL2200591

FC(F)(F)c1cnc2ccccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.52
PDGFRB P09619 4/20 0.46
PDGFRA P16234 4/20 0.46
MGAM O43451 1/20 0.46
SLC22A12 Q96S37 1/20 0.46
ALDH1A1 P00352 2/20 0.44
PPARD Q03181 1/20 0.44
CNR1 P21554 2/20 0.44
CNR2 P34972 2/20 0.44
ALPL P05186 1/20 0.44
MAPT P10636 2/20 0.44
USP2 O75604 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 2/20 0.43
CYP2A6 P11509 1/20 0.43
GLA P06280 1/20 0.43
ACHE P22303 1/20 0.43
BIRC5 O15392 1/20 0.42
MET P08581 1/20 0.42
BACE1 P56817 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28009315 0.98 CYP1A2 (0.50) CYP1A2PDGFRBPDGFRAMGAMSLC22A12
SCHEMBL29033265 0.86 CYP1A2 (0.50) CYP1A2PDGFRBPDGFRAMGAMSLC22A12
SCHEMBL27536533 0.82 CYP1A2 (0.53) CYP1A2PDGFRBPDGFRAMGAMALDH1A1
SCHEMBL17634096 0.80 PDGFRB (0.65) CYP1A2PDGFRBPDGFRACNR1CNR2
SCHEMBL26829686 0.80 PDGFRB (0.65) CYP1A2PDGFRBPDGFRACNR1CNR2
SCHEMBL26819923 0.80 PDGFRB (0.65) CYP1A2PDGFRBPDGFRACNR1CNR2
SCHEMBL5720471 0.80 CYP1A2 (0.52) CYP1A2PDGFRBPDGFRAMGAMALDH1A1
SCHEMBL418110 0.80 CYP1A2 (0.57) CYP1A2PDGFRBPDGFRAMGAMALDH1A1
SCHEMBL29378165 0.78 BIRC5 (0.60) PDGFRBPDGFRAHPGDCYP2A6BIRC5
SCHEMBL14026098 0.77 PDGFRB (0.49) PDGFRBPDGFRAALDH1A1MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119899150-A Synthetic method and application of 3-trifluoromethyl quinoline compound 遵义医科大学 2025-04-29 CN claimed
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 US claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
CN-119899150-B Synthetic method and application of 3-trifluoromethyl quinoline compound 遵义医科大学 2025-12-02 CN disclosed
CN-119899150-B Synthetic method and application of 3-trifluoromethyl quinoline compound 遵义医科大学 2025-12-02 CN disclosed
CN-119899150-A Synthetic method and application of 3-trifluoromethyl quinoline compound 遵义医科大学 2025-04-29 CN disclosed
CN-119899150-A Synthetic method and application of 3-trifluoromethyl quinoline compound 遵义医科大学 2025-04-29 CN disclosed
CN-119899150-A Synthetic method and application of 3-trifluoromethyl quinoline compound 遵义医科大学 2025-04-29 CN disclosed
WO-2025011553-A1 AZOLE COMPOUNDS, SYNTHESIS THEREFOR AND PHARMACEUTICAL USE THEREOF 四川农业大学 2025-01-16 WO disclosed
CN-116874430-B Azole compound and synthesis and pharmaceutical application thereof 四川农业大学 2024-12-24 CN disclosed
EP-1868998-A2 NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS Insa Rouen (FR) 2007-12-26 EP disclosed
EP-1731507-A1 New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents Institut National des Sciences Appliquees de Rouen (INSA) (FR) 2006-12-13 EP disclosed
WO-2006103120-A2 NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS INSA ROUEN (FR) 2006-10-05 WO disclosed
EP-0363212-B1 Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components MITSUI TOATSU CHEMICALS (JP) 1995-01-04 EP disclosed
US-5204348-A Quinoline derivatives MITSUI TOATSU CHEMICALS INC. (JP) 1993-04-20 US disclosed
US-5112817-A Anticancer Drug Potentiators MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1992-05-12 US disclosed
EP-0363212-A2 Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components MITSUI TOATSU CHEMICALS, Inc. (JP) 1990-04-11 EP disclosed
US-4396620-A BACTERICIDES ELI LILLY AND COMPANY (US) 1983-08-02 US disclosed
US-4382931-A 3'-Substituted quinolinium cephalosporins ELI LILLY AND COMPANY (US) 1983-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH CYP1A2 611/4885PDGFRB 1794/4885PDGFRA 2131/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR CYP1A2 2553/4885PDGFRB 4797/4885PDGFRA 4488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.